The inhibitory effects of the standardized extracts of Ginkgo biloba on aaromatase activity in JEG-3 human choriocarcinoma cells

Phytotherapy Research

Volumn 27, Issue 12, 2013, Pages 1756-1762

  Kim, Mi Jie ^a   Park, Yong Joo ^a   Chung, Kyu Hyuck ^a   Oh, Seung Min ^b  

^a Sungkyunkwan University   (South Korea)

^b Hoseo University   (South Korea)

Author keywords

aromatase inhibitors; CYP19; Extracts of Ginkgo biloba; JEG 3 cells; phytoestrogens

Indexed keywords

AROMATASE; GINKGO BILOBA EXTRACT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHORIOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MICROSOME; NUCLEOTIDE SEQUENCE; PHYTOCHEMISTRY; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING;

GINKGO BILOBA;

AROMATASE INHIBITORS; CYP19; EXTRACTS OF GINKGO BILOBA; JEG-3 CELLS; PHYTOESTROGENS;

AROMATASE; AROMATASE INHIBITORS; CELL LINE, TUMOR; CHORIOCARCINOMA; ESTROGENS; FEMALE; GINKGO BILOBA; HUMANS; MICROSOMES; PLANT EXTRACTS; PROMOTER REGIONS, GENETIC; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 84890553485     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4927     Document Type: Article

References (53)

1. Adlercreutz H, Bannwart C, Wahala K, et al,. 1993. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44: 147-153.
2. Amin A, Abraham C, Hamza AA, et al,. 2012. A standardized extract of Ginkgo biloba neutralizes cisplatin-mediated reproductive toxicity in rats. J Biomed Biotechnol 2012: 362049.
3. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ,. 2000. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 66: 769-777.
4. Baum M, Budzar AU, Cuzick J, et al,. 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139.
5. Baum M, Buzdar A, Cuzick J, et al,. 2003. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802-1810.
6. Brayboy JR, Chen XW, Lee YS, Anderson JJB,. 2001. The protective effects of Ginkgo biloba extract (EGb 761) against free radical damage to osteoblast-like bone cells (MC3T3-E1) and the proliferative effects of EGb 761 on these cells. Nutrition Research 21: 1275-1285.
7. Bulun SE, Lin Z, Imir G, et al,. 2005. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57: 359-383.
8. Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H, Bulun SE,. 2009. Regulation of breast cancer-associated aromatase promoters. Cancer Lett 273: 15-27.
9. Choi HK, Roh SH, Kim HG, Han EH, Jeong HG, Kang KW,. 2008. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells. Endocr Relat Cancer 15: 139-147.
10. Colleoni M, Giobbie-Hurder A,. 2010. Benefits and adverse effects of endocrine therapy. Annals of Oncology 21: vii107-vii111.
11. Coombes RC, Hall E, Gibson LJ, et al,. 2004. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092.
12. DeFeudis FV, Drieu K,. 2000. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1: 25-58.
13. DeFeudis FV, Papadopoulos V, Drieu K,. 2003. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol 17: 405-417.
14. Dixon-Shanies D, Shaikh N,. 1999. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 6: 1383-1387.
15. Dubey AK, Shankar PR, Upadhyaya D, Deshpande VY,. 2004. Ginkgo biloba - an appraisal. Kathmandu Univ Med J (KUMJ) 2: 225-229.
16. Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M,. 2010. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17: 356-362.
17. Goss PE, Ingle JN, Martino S, et al,. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802.
18. Grube BJ, Eng ET, Kao YC, Kwon A, Chen S,. 2001. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 131: 3288-3293.
19. Howell A, Buzdar A,. 2005. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 93: 237-247.
20. Iwase H, Zhang Z, Omoto Y, et al,. 2003. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 52 (Suppl 1): S34-8.
21. Jang M, Cai L, Udeani GO, et al,. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
22. Janni W, Hepp P,. 2010. Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 36: 249-261.
23. Johnston SR, Dowsett M,. 2003. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3: 821-831.
24. Kamdem LK, Flockhart DA, Desta Z,. 2011. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 39: 98-105.
25. Kao YC, Zhou C, Sherman M, Laughton CA, Chen S,. 1998. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ Health Perspect 106: 85-92.
26. Khan SI, Zhao J, Khan IA, Walker LA, Dasmahapatra AK,. 2011. Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. Reprod Biol Endocrinol 9: 91.
27. Kijima I, Phung S, Hur G, Kwok SL, Chen S,. 2006. Grape seed extract is an aromatase inhibitor and a suppressor of aromatase expression. Cancer Res 66: 5960-5967.
28. Laville N, Balaguer P, Brion F, et al,. 2006. Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. Toxicology 228: 98-108.
29. Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G,. 2001. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities. Life Sci 68: 751-761.
30. Lee EK, Kook SH, Park YL, Bae WG,. 2006. Endoscopy-assisted breast-conserving surgery for early breast cancer. World J Surg 30: 957-964.
31. Lephart ED, Simpson ER,. 1991. Cytochrome P450 [45] Assay of Aromatase activity. In Methods in enzymology, Michael EFJ, Waterman R, (eds). Academic Press. Inc: Waltham, Massachusetts; 206: 477-483.
32. Lucinda LM, Aarestrup BJ, Peters VM, de Paula Reis JE, de Oliveira RS, de Oliveira Guerra M,. 2012. The Effect of the Ginkgo biloba Extract in the Expression of Bax, Bcl-2 and Bone Mineral Content of Wistar Rats with Glucocorticoid-induced Osteoporosis. Phytother Res. DOI: 10.1002/ptr.4747.
33. Macedo LF, Sabnis G, Brodie A,. 2009. Aromatase inhibitors and breast cancer. Ann N Y Acad Sci 1155: 162-173.
34. Mokbel R, Karat I, Mokbel K,. 2006. Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update. Int Semin Surg Oncol 3: 31.
35. Mu YM, Yanase T, Nishi Y, et al,. 2000. A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells. Mol Cell Endocrinol 166: 137-145.
36. Oh SM, Chung KH,. 2006. Antiestrogenic activities of Ginkgo biloba extracts. J Steroid Biochem Mol Biol 100: 167-176.
37. Oh SM, Chung KH,. 2004. Estrogenic activities of Ginkgo biloba extracts. Life Sci 74: 1325-1335.
38. Oh SM, Kim HR, Chung KH,. 2008. Effects of ginkgo biloba on in vitro osteoblast cells and ovariectomized rat osteoclast cells. Arch Pharm Res 31: 216-224.
39. Plant N,. 2004. Strategies for using in vitro screens in drug metabolism. Drug Discov Today 9: 328-336.
40. Rice S, Whitehead SA,. 2006. Phytoestrogens and breast cancer - promoters or protectors? Endocr Relat Cancer 13: 995-1015.
41. Sanderson JT, Letcher RJ, Heneweer M, Giesy JP, van den Berg M,. 2001. Effects of chloro-s-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environ Health Perspect 109: 1027-1031.
42. Satoh K, Sakamoto Y, Ogata A, et al,. 2002. Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats. Food Chem Toxicol 40: 925-933.
43. Schmidt S, Michna H, Diel P,. 2005. Combinatory effects of phytoestrogens and 17beta-estradiol on proliferation and apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 94: 445-449.
44. Siegel R, Naishadham D, Jemal A,. 2012. Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
45. Smith JV, Luo Y,. 2004. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 64: 465-472.
46. Toda K, Akira S, Kishimoto T, et al,. 1995. Identification of a transcriptional regulatory factor for human aromatase cytochrome P450 gene expression as nuclear factor interleukin-6 (NF-IL6), a member of the CCAAT/enhancer-binding protein family. Eur J Biochem 231: 292-299.
47. Wang C, Kurzer MS,. 1998. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr Cancer 31: 90-100.
48. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS,. 1994. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 50: 205-212.
49. Wang Y, Lee KW, Chan FL, Chen S, Leung LK,. 2006. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci 92: 71-77.
50. Wang Y, Leung LK,. 2007. Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells. Toxicol Lett 173: 175-180.
51. Wang Y, Ye L, Leung LK,. 2008. A positive feedback pathway of estrogen biosynthesis in breast cancer cells is contained by resveratrol. Toxicology 248: 130-135.
52. Watanabe M, Nakajin S,. 2004. Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R. J Endocrinol 180: 125-133
53. Way TD, Lee HH, Kao MC, Lin JK,. 2004. Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. Eur J Cancer 40: 2165-2174.